<DOC>
	<DOCNO>NCT02151682</DOCNO>
	<brief_summary>Tapentadol already study adult . This study need find tapentadol work safe use child adolescents long-term pain . During first 2 week study ( Part 1 ) , participant give either tapentadol morphine prolonged-release tablet . Assignment do randomly ( like toss coin ) . The participant caregiver know medication taking . The primary endpoint base data collect Part 1 trial . If eligible willing , participant Part 1 enter 12 month follow-up period ( Part 2 ) . In Part 2 trial participant treat tapentadol prolonged release tablet standard care ( observation arm ) .</brief_summary>
	<brief_title>An Open-label Trial , Enrolling Subjects Aged 6 Years Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment , Evaluate Safety Efficacy Tapentadol PR Versus Morphine PR , Followed Open-label Extension .</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>Part 1 Randomized openlabel , active comparator control treatment Participants eligible trial follow apply : Informed consent ( applicable assent ) obtain . Male female participant least 6 year age Enrollment Visit le 18 year age Day 14 . Participant underlying longterm pain condition , accord judgment investigator , expect require twicedaily prolong release opioid treatment least end 14day Treatment Period . Participant swallow tablet appropriate size . Participant able participate trial plan willing comply requirement protocol include refrain drinking beverage contain alcohol recreational intake drug study medication . Participants must satisfy follow criterion allocation treatment : Less 18 year age . No opioid intake last calculated morphine equivalent dose le 3.5 mg/kg per day . Participant body weight least 17.5 kg . If female childbearing potential ( post menarchal surgically incapable childbearing ) sexually active , must practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch ) allocation study medication end intake study medication . If female post menarchal old 12 year , negative urine pregnancy test day day allocation study medication . Part 2 Inclusion criterion Tapentadol Openlabel extension period : Participant complete 14day Treatment Period . Participant still need prolonged release opioid treatment . Participant meet compulsory discontinuation criterion . Participants eligible trial follow apply . The following checked enrollment : Has previously enrol trial previous trial tapentadol . Has clinically relevant history hypersensitivity , allergy , contraindication morphine tapentadol ingredient , include galactose intolerance ( see investigator 's brochure tapentadol PR summary product characteristic morphine PR ) , naloxone . History current condition one following : Seizure disorder epilepsy . Serotonin syndrome . Traumatic hypoxic brain injury , brain contusion , stroke , transient ischemic attack , intracranial hematoma , posttraumatic amnesia , brain neoplasm , episode ( ) 24 hour duration unconsciousness . History current condition one following : Moderate severe renal hepatic impairment . Abnormal pulmonary function clinically relevant respiratory disease ( e.g. , acute severe bronchial asthma , hypercapnia ) History alcohol drug abuse investigator 's judgment , base history physical examination . Drugs abuse detect urine screen unless explain allow concomitant medication Participant : A clinically relevant abnormal electrocardiogram . Signs preexcitation syndrome . Brugada 's syndrome . QT QTcF ( Fridericia ) interval great 470 ms. Any surgery schedule first 14 day trial expect require postsurgical intensive care unit ( ICU ) treatment , require postsurgical parenteral paintreatment , may , affect safety participant . Participant able understand comply protocol appropriate age subject subject cognitively impaired investigator 's judgment comply protocol . Participant , parent legal representative employee investigator trial site , direct involvement propose trial study direction investigator trial site , family member employee investigator . The following checked enrollment allocation visit : Has concomitant disease disorder ( e.g. , endocrine , metabolic , neurological , psychiatric , infection ) opinion investigator may affect compromise subject safety trial participation . Pancreatic/biliary tract disease ( e.g. , pancreatitis ) paralytic ileus . Intake forbidden concomitant medication/use forbidden therapy ( see synopsis section Concomitant medications/therapies ) . Female participant breastfeeding child . The following checked allocation treatment visit : Has receive drug use medical device approve human use within 30 day prior visit . Based data local laboratory , one : Total serum bilirubin great 2.0 mg/dL . Serum albumin less 2.8 g/dL . Aspartate transaminase alanine transaminase great 5 time upper limit normal . Based data local laboratory , creatinine clearance le 30 mL/min per 1.73 m2 ( calculate accord formula appropriate respective age group ) . If participant suffers noncancer relate pain : participation interventional clinical trial within 30 day prior visit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic pain</keyword>
	<keyword>opioid</keyword>
</DOC>